Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Hisamitsu Pharmaceutical Co's Debt-to-Equity or its related term are showing as below:
FSE:4530'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.01 Max: 0.01
Current: 0.01
During the past 13 years, the highest Debt-to-Equity Ratio of Hisamitsu Pharmaceutical Co was 0.01. The lowest was 0.01. And the median was 0.01.
FSE:4530's Debt-to-Equity is ranked better than 99.88% of 813
companies
in the Drug Manufacturers industry
Industry Median: 0.27
vs FSE:4530: 0.01
Hisamitsu Pharmaceutical Co (FSE:4530) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Hisamitsu Pharmaceutical Co Debt-to-Equity Related Terms
Hisamitsu Pharmaceutical Co Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FSE:4530 vs ESPR, AMPH, ETON: Debt-to-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Hisamitsu Pharmaceutical Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hisamitsu Pharmaceutical Co Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hisamitsu Pharmaceutical Co's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Hisamitsu Pharmaceutical Co's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hisamitsu Pharmaceutical Co (FSE:4530) has a Debt-to-Equity of 0.01 as of Nov. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Hisamitsu Pharmaceutical Co and its competitors. This is near median its historical median of 0.01. Over the past decade, Hisamitsu Pharmaceutical Co's Debt-to-Equity has ranged from 0.01 to 0.01. According to the industry distribution chart, Hisamitsu Pharmaceutical Co ranks #1 out of 813 companies in the Drug Manufacturers industry, placing it in the top 0.099999999999994%.
Is Hisamitsu Pharmaceutical Co's Debt-to-Equity too high?
Hisamitsu Pharmaceutical Co's current Debt-to-Equity of 0.01 is near median its 10-year median of 0.01. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.01. The Drug Manufacturers industry median Debt-to-Equity is 0.27. Hisamitsu Pharmaceutical Co's value of 0.01 is 96.3% below this industry median. Based on the distribution chart, Hisamitsu Pharmaceutical Co ranks #1 out of 813 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Hisamitsu Pharmaceutical Co has a GF Score™ of 89/100, reflecting its overall financial health beyond just this single metric.
How does Hisamitsu Pharmaceutical Co's Debt-to-Equity compare to ESPR and AMPH?
According to the Drug Manufacturers industry distribution chart, Hisamitsu Pharmaceutical Co ranks #1 out of 813 companies for Debt-to-Equity. This places Hisamitsu Pharmaceutical Co in the top 0% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.27. Hisamitsu Pharmaceutical Co's value of 0.01 is 96.3% below this benchmark. Historically, Hisamitsu Pharmaceutical Co's own Debt-to-Equity has ranged from 0.01 to 0.01 over the past decade. While the company's 10-year median is 0.01 vs. the industry median of 0.27, Hisamitsu Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hisamitsu Pharmaceutical Co's current Debt-to-Equity of 0.01 is 96.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Hisamitsu Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hisamitsu Pharmaceutical Co's current Debt-to-Equity is 0.01, which is near median its own 10-year median of 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hisamitsu Pharmaceutical Co stock overvalued right now?
Hisamitsu Pharmaceutical Co (FSE:4530) has a current Debt-to-Equity of 0.01. The stock's GF Value™ is 円3,237.07, compared to a current price of 円3,975.00 — trading 22.8% above its estimated fair value. The current Debt-to-Equity is 0.01, which is near median its 10-year median of 0.01 and 96.3% below the Drug Manufacturers industry median of 0.27. Hisamitsu Pharmaceutical Co's overall GF Score™ is 89/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Hisamitsu Pharmaceutical Co (FSE:4530), the current Debt-to-Equity is 0.01 as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hisamitsu Pharmaceutical Co (FSE:4530) Overvalued in 2026?
Based on GuruFocus' analysis, Hisamitsu Pharmaceutical Co stock appears to be overvalued.
The current stock price of 円3,975.00 is trading 22.8% above its estimated GF Value™ of 円3,237.07.
Key valuation signals for FSE:4530:
Debt-to-Equity: 0.01 (near median its 10-year median of 0.01)
GF Value™: 円3,237.07 vs. price of 円3,975.00 (22.8% above fair value)
Industry Position: 96.3% below the Drug Manufacturers median (#1 of 813)
No single metric tells the full story. See the FSE:4530 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hisamitsu Pharmaceutical Co Inc is engaged in the research, development, manufacturing, procurement, and sale of pharmaceutical products. The company operates a single business segment, focusing on medical and general pharmaceuticals both in Japan and overseas. It markets drugs under the Salonpas, Nobinobi / Salonsip, Butenalock, and Mohrus brands, which mainly serve topical medication needs with pain relief creams, gels, sprays, lotions, and ointments.
89GF Score
Get the complete analysis for FSE:4530
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FSE:4530 has been successfully added to your 
